Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari & Farhad Jadidi-Niaragh. (2022) The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert Opinion on Therapeutic Targets 26:12, pages 1057-1071.
Read now
Read now
Bing Zhai, Chunmei Hou, Ruonan Xu, Ying Fang, He Xiao, Guojiang Chen, Xiaoqian Wang, Ning Ma, Gencheng Han & Renxi Wang. (2019) Loc108167440 suppressed myeloma cell growth by P53-mediated apoptosis. Leukemia & Lymphoma 60:10, pages 2541-2548.
Read now
Read now
Jessica Liegel, David Avigan & Jacalyn Rosenblatt. (2018) Cellular immunotherapy as a therapeutic approach in multiple myeloma. Expert Review of Hematology 11:7, pages 525-536.
Read now
Read now
CJ Turtle, RD Brown, DE Joshua & DNJ Hart. (2004) DC in multiple myeloma immunotherapy. Cytotherapy 6:2, pages 128-137.
Read now
Read now
Articles from other publishers (52)
Niyati Seshagiri Sharma & Bibha Choudhary. (2023) Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma. Biomolecules 13:11, pages 1629.
Crossref
Crossref
Mahya Aghaee, Urszula Ledzewicz, Michael Robbins, Natalie Bezman, Hearn Jay Cho & Helen Moore. (2023) Determining optimal combination regimens for patients with multiple myeloma. European Journal of Pharmaceutical Sciences 187, pages 106492.
Crossref
Crossref
Cinnie Yentia Soekojo & Wee Joo Chng. (2022) The evolution of immune dysfunction in multiple myeloma. European Journal of Haematology 109:5, pages 415-424.
Crossref
Crossref
Olayinka O. Adebayo, Eric B. Dammer, Courtney D. Dill, Adeyinka O. Adebayo, Saheed O. Oseni, Ti’ara L. Griffen, Adaugo Q. Ohandjo, Fengxia Yan, Sanjay Jain, Benjamin G. Barwick, Rajesh Singh, Lawrence H. Boise & James W. Lillard, Jr.. (2022) Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. Cancers 14:9, pages 2228.
Crossref
Crossref
Jia Tan, Binbin Ding, Bo Teng, Ping'an Ma & Jun Lin. (2022) Understanding Structure–Function Relationships of Nanoadjuvants for Enhanced Cancer Vaccine Efficacy. Advanced Functional Materials 32:16.
Crossref
Crossref
Ksenia Bezverbnaya, Duane Moogk, Derek Cummings, Christopher L. Baker, Craig Aarts, Galina Denisova, Michael Sun, Jamie D. McNicol, Rebecca C. Turner, Anthony F. Rullo, S. Ronan Foley & Jonathan L. Bramson. (2021) Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. Cytotherapy 23:9, pages 820-832.
Crossref
Crossref
Gregorio Barilà, Laura Pavan, Susanna Vedovato, Tamara Berno, Mariella Lo Schirico, Massimiliano Arangio Febbo, Antonella Teramo, Giulia Calabretto, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Anna Fregnani, Sabrina Manni, Valentina Trimarco, Samuela Carraro, Monica Facco, Francesco Piazza, Gianpietro Semenzato & Renato Zambello. (2021) Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. Frontiers in Oncology 11.
Crossref
Crossref
Claudio Ortolani. 2021. Flow Cytometry of Hematological Malignancies. Flow Cytometry of Hematological Malignancies
301
427
.
Alireza Isazadeh, Saba Hajazimian, Hamid Garshasbi, Behrouz Shadman, Amir Baghbanzadeh, Reza Chavoshi, Sina Taefehshokr, Mahdieh Farhoudi Sefidan Jadid, Khalil Hajiasgharzadeh & Behzad Baradaran. (2020) Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma. Journal of Cellular Physiology 236:2, pages 791-805.
Crossref
Crossref
Jessica J. Liegel & David E. Avigan. 2020. Cancer Immunology. Cancer Immunology
75
102
.
Haimeng Yan, Gaofeng Zheng, Jianwei Qu, Yang Liu, Xi Huang, Enfan Zhang & Zhen Cai. (2019) Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis. Journal of Cellular Physiology 234:12, pages 23785-23797.
Crossref
Crossref
Manisha Bhutani, David Foureau, Qing Zhang, Myra Robinson, Adina S. Wynn, Nury M. Steuerwald, Lawrence J. Druhan, Fei Guo, Katherine Rigby, Mitchell Turner, Daniel Slaughter, Reed Friend, Shebli Atrash, James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Peter M. Voorhees & Saad Z. Usmani. (2019) Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma. Biology of Blood and Marrow Transplantation 25:3, pages 459-465.
Crossref
Crossref
Myo Htut. (2019) Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?. Current Hematologic Malignancy Reports 14:1, pages 1-10.
Crossref
Crossref
Dawn Swan, Kevin Lynch, Mark Gurney & Michael O’Dwyer. (2019) Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. Therapeutic Advances in Hematology 10, pages 204062071985417.
Crossref
Crossref
Jacalyn Rosenblatt & David Avigan. (2019) Cellular Immunotherapy for Multiple Myeloma. The Cancer Journal 25:1, pages 38-44.
Crossref
Crossref
Jill Gallaher, Kamila Larripa, Marissa Renardy, Blerta Shtylla, Nessy Tania, Diana White, Karen Wood, Li Zhu, Chaitali Passey, Michael Robbins, Natalie Bezman, Suresh Shelat, Hearn Jay Cho & Helen Moore. (2018) Methods for determining key components in a mathematical model for tumor–immune dynamics in multiple myeloma. Journal of Theoretical Biology 458, pages 31-46.
Crossref
Crossref
Xiao-Ying Qin, Jin Lu, Guo-Xuan Li, Lei Wen, Yang Liu, Lan-Ping Xu, Ying-Jun Chang, Kai-Yan Liu, Zheng-Fan Jiang & Xiao-Jun Huang. (2017) CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology 97:3, pages 485-495.
Crossref
Crossref
Inger S. Nijhof, Niels W. C. J. van de Donk, Sonja Zweegman & Henk M. Lokhorst. (2017) Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs 78:1, pages 19-37.
Crossref
Crossref
Jill Gallaher, Kamila Larripa, Urszula Ledzewicz, Marissa Renardy, Blerta Shtylla, Nessy Tania, Diana White, Karen Wood, Li Zhu, Chaitali Passey, Michael Robbins, Natalie Bezman, Suresh Shelat, Hearn Jay Cho & Helen Moore. 2018. Understanding Complex Biological Systems with Mathematics. Understanding Complex Biological Systems with Mathematics
89
122
.
Catherine M. GavileBenjamin G. BarwickScott NewmanPaola Neri, Ajay K. NookaSagar LonialKelvin P. Lee & Lawrence H. Boise. (2017) CD86 regulates myeloma cell survival. Blood Advances 1:25, pages 2307-2319.
Crossref
Crossref
Don M. BensonJrJr. (2016) Checkpoint inhibition in myeloma. Hematology 2016:1, pages 528-533.
Crossref
Crossref
Claudia Zelle-Rieser, Shanmugapriya Thangavadivel, Rainer Biedermann, Andrea Brunner, Patrizia Stoitzner, Ella Willenbacher, Richard Greil & Karin Jöhrer. (2016) T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Bruno PaivaMaría Victoria MateosLuis Ignacio Sanchez-AbarcaNoemi PuigMaría-Belén VidrialesLucía López-CorralLuis A. CorcheteMiguel T. HernandezJoan BargayFelipe de ArribaJavier de la RubiaAna-Isabel TeruelPilar GiraldoLaura RosiñolFelipe ProsperAlbert OriolJosé HernándezGraça EstevesJuan José Lahuerta, Joan BladéJose Antonio Perez-Simon & Jesús F. San Miguel. (2016) Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood 127:9, pages 1151-1162.
Crossref
Crossref
Frederick L Locke, Meghan Menges, Anandharaman Veerapathran, Domenico Coppola, Dmitry Gabrilovich & Claudio Anasetti. (2015) Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. Journal for Immunotherapy of Cancer 3:1.
Crossref
Crossref
T Dosani, M Carlsten, I Maric & O Landgren. (2015) The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer Journal 5:4, pages e306-e306.
Crossref
Crossref
Wieger J. Norde, Willemijn Hobo & Harry Dolstra. 2015. Resistance of Cancer Cells to CTL-Mediated Immunotherapy. Resistance of Cancer Cells to CTL-Mediated Immunotherapy
31
58
.
Frederick L Locke, Taiga Nishihori, Melissa Alsina & Mohamed A Kharfan-Dabaja. (2013) Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy 5:9, pages 1005-1020.
Crossref
Crossref
Alan G. Ramsay. (2013) Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. British Journal of Haematology 162:3, pages 313-325.
Crossref
Crossref
Wieger J. Norde, Willemijn Hobo, Robbert van der Voort & Harry Dolstra. (2012) Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 120:4, pages 728-736.
Crossref
Crossref
Megan E. Prosser, Christine E. Brown, Andrew F. Shami, Stephen J. Forman & Michael C. Jensen. (2012) Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology 51:3-4, pages 263-272.
Crossref
Crossref
Lidia Karabon, Edyta Pawlak-Adamska, Anna Tomkiewicz, Anna Jedynak, Marek Kielbinski, Dariusz Woszczyk, Stanisław Potoczek, Anna Jonkisz, Kazimierz Kuliczkowski & Irena Frydecka. (2011) Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population. Pathology & Oncology Research 18:2, pages 219-226.
Crossref
Crossref
Claudio Ortolani. 2011. Flow Cytometry of Hematological Malignancies. Flow Cytometry of Hematological Malignancies
160
300
.
Amir Sharabi & Nechama Haran-Ghera. (2011) Immune Recovery after Cyclophosphamide Treatment in Multiple Myeloma: Implication for Maintenance Immunotherapy. Bone Marrow Research 2011, pages 1-7.
Crossref
Crossref
Amir Sharabi & Nechama Haran Ghera. 2010.
1
37
.
Guy Pratt, Oliver Goodyear & Paul Moss. (2007) Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology 138:5, pages 563-579.
Crossref
Crossref
Antonio Palumbo, Sara Bringhen, Patrizia Falco, Federica Cavallo, Maria Teresa Ambrosini, Ilaria Avonto, Francesca Gay, Tommaso Caravita, Benedetto Bruno & Mario Boccadoro. (2007) Time to first disease progression, but not β2‐microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 110:4, pages 824-829.
Crossref
Crossref
Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S. Oster, Odelia Katz, Amos Cohen, Elizabeth Naparstek, Drorit Neumann & Moshe Mittelman. (2006) Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?. British Journal of Haematology 135:5, pages 660-672.
Crossref
Crossref
Claudia M. Kowolik, Max S. Topp, Sergio Gonzalez, Timothy Pfeiffer, Simon Olivares, Nancy Gonzalez, David D. Smith, Stephen J. Forman, Michael C. Jensen & Laurence J.N. Cooper. (2006)
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances
In vivo
Persistence and Antitumor Efficacy of Adoptively Transferred T Cells
. Cancer Research 66:22, pages 10995-11004.
Crossref
Crossref
Kristen J. Radford, Frank Vari & Derek N.J. Hart. (2005) Vaccine strategies to treat lymphoproliferative disorders. Pathology 37:6, pages 534-550.
Crossref
Crossref
Brian G.M. Durie. (2005) New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals. Clinical Lymphoma and Myeloma 6:3, pages 181-190.
Crossref
Crossref
Yu-hua Qiu, Zhong-wen Sun, Qin Shi, Cheng-hai Su, Yong-jing Chen, Yun-jie Shi, Ran Tao, Yan Ge & Xue-guang Zhang. (2005) Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28. Cellular Immunology 236:1-2, pages 154-160.
Crossref
Crossref
Gema Mateo, Mariana Castellanos, Ana Rasillo, Norma C. Gutiérrez, Ma. Angeles Montalbán, Ma. Luisa Martín, Jesús Ma. Hernández, Ma. Consuelo López-Berges, Laura Montejano, Joan Bladé, Ma. Victoria Mateos, Anna Sureda, Javier de la Rubia, Joaquín Díaz-Mediavilla, Atanasio Pandiella, Juan José Lahuerta, Alberto Orfao & Jesús F. San Miguel. (2005) Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. Clinical Cancer Research 11:10, pages 3661-3667.
Crossref
Crossref
M Pérez-Andrés, J Almeida, M Martín-Ayuso, M J Moro, G Martín-Nuñez, J Galende, D Borrego, M J Rodríguez, F Ortega, J Hernandez, I Moreno, M Domínguez, G Mateo, J F San Miguel & A Orfao. (2005) Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19:3, pages 449-455.
Crossref
Crossref
Brian G.M. DurieJoth JacobsonBart BarlogieJohn Crowley. (2004) Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials. Journal of Clinical Oncology 22:10, pages 1857-1863.
Crossref
Crossref
Fariba Mozaffari, Lotta Hansson, Shahryar Kiaii, Xiuli Ju, Eva D. Rossmann, Hodjattallah Rabbani, Håkan Mellstedt & Anders Österborg. (2004) Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. British Journal of Haematology 124:3, pages 315-324.
Crossref
Crossref
Asad Bashey, Mark J. Cantwell & Thomas J. Kipps. (2002) Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. British Journal of Haematology 118:2, pages 506-513.
Crossref
Crossref
Ross D. BrownBelinda PopeAllan MurrayWarren EsdaleDaniel M. SzeJohn GibsonP. Joy HoDerek HartDoug Joshua. (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 98:10, pages 2992-2998.
Crossref
Crossref
Virginia Smith ShapiroMarianne Newton MollenauerArthur Weiss. (2001) Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood 98:1, pages 187-193.
Crossref
Crossref
Takeshi Yamanaka, Anne Straumfors, H. Craig Morton, Olav Fausa, Per Brandtzaeg & Inger Nina Farstad. (2001) M cell pockets of human Peyer's patches are specialized extensions of germinal centers. European Journal of Immunology 31:1, pages 107-117.
Crossref
Crossref
Belinda PopeRoss D. BrownJohn GibsonEdna YuenDoug Joshua. (2000) B7-2–positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 96:4, pages 1274-1279.
Crossref
Crossref
Belinda PopeRoss D. BrownJohn GibsonEdna YuenDoug Joshua. (2000) B7-2–positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 96:4, pages 1274-1279.
Crossref
Crossref
Thomas E. Witzig. (1999) THE ROLE OF ADHESION RECEPTORS IN THE PATHOGENESIS OFMULTIPLE MYELOMA. Hematology/Oncology Clinics of North America 13:6, pages 1127-1143.
Crossref
Crossref